Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting now · Phase 2

Conditions studied: Hepatocellular Carcinoma, Biliary Tract Cancer

In brief

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.

Key facts

Study ID
NCT05733598
Run by
Replimune, Inc.
People needed
60
Starts
2024-08-01
Expected to finish
2028-07-01
Last updated by the study team
2026-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.